OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections.

Autor: Kers JA; Intrexon Corp., Industrial Products Division, South San Francisco, CA, United States of America., DeFusco AW; Oragenics, Inc, Alachua, FL, United States of America., Park JH; Oragenics, Inc, Alachua, FL, United States of America., Xu J; University of Massachusetts Lowell, One University Avenue, Lowell, MA, United States of America., Pulse ME; PreClinical Services, UNT System College of Pharmacy, Fort Worth, TX, United States of America., Weiss WJ; PreClinical Services, UNT System College of Pharmacy, Fort Worth, TX, United States of America., Handfield M; Oragenics, Inc, Alachua, FL, United States of America.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2018 Jun 12; Vol. 13 (6), pp. e0197467. Date of Electronic Publication: 2018 Jun 12 (Print Publication: 2018).
DOI: 10.1371/journal.pone.0197467
Abstrakt: Lantibiotics continue to offer an untapped pipeline for the development of novel antibiotics. We report here the discovery of a novel lantibiotic for the treatment of C. difficile infection (CDI). The leads were selected from a library of over 300 multiple substitution variants of the lantibiotic Mutacin 1140 (MU1140). Top performers were selected based on testing for superior potency, solubility, manufacturability, and physicochemical and/or metabolic stability in biologically-relevant systems. The best performers in vitro were further evaluated orally in the Golden Syrian hamster model of CDAD. In vivo testing ultimately identified OG716 as the lead compound, which conferred 100% survival and no relapse at 3 weeks post infection. MU1140-derived variants are particularly attractive for further clinical development considering their novel mechanism of action.
Competing Interests: JX, MEP and WJW had a financial interest in this study as Oragenics sponsored work performed in their respective laboratories. JAK was an Intrexon employees during the data collection and initial data analysis. AWD was an Oragenics stockholder and employee during data collection and initial data analysis. JHP and MH had a financial interest in Oragenics as stockholders and employees during data collection, analysis and writing of the manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje